Floatz Rating
D30/100
Confidence
Indicative
Sponsor
IRCCS San Raffaele
Modality
Small molecule
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05907655CT.gov Study of the Glymphatic System in Migraine | — | Unknown | — | — | — |
NCT05718310CT.gov Habituation of the Nociceptive Blink Reflex in Experimentally Induced Migraine Attack | — | Unknown | — | — | — |
NCT04220606CT.gov 1H Magnetic Resonance Spectroscopy in Migraine Patients | — | Completed | — | — | — |
NCT00363571CT.gov The Effect of Glyceryl Trinitate and Diamox on Cerebral Haemodynamics. | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Migraine Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nitroglycerin Tablets (this asset) | IRCCS San Raffaele | N/A | D · 30 |
| Atogepant | Stanford University | P4 | A |
| Zolmitriptan | Zosano Pharma Corporation | P4 | A |
| Rizatriptan | Antonios Likourezos | P4 | A |
| Naproxen | IRCCS San Raffaele Roma | P4 | A |
| Eptinezumab | Stanford University | P4 | BBB |
| Ubrogepant | H. Lundbeck A/S | P4 | BBB |
| Dfn-11 (Sumatriptan Injection) | IRCCS San Raffaele Roma | P4 | BBB |
| Eletriptan | Boehringer Ingelheim | P4 | BBB |
+42 more in the Migraine Disorder cohort
Other indications for Nitroglycerin Tablets
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Coronary Artery Disorder | — | P4 | BB · 65 |
| Sickle Cell Disease | — | P2 | B · 57 |
| Stroke Disorder | — | P3 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nitroglycerin Tablets in Migraine Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nitroglycerin-tablets-migraine-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →